Possibia

2492503

Last Update Posted: 2015-07-08

Recruiting status is unknown

Females

accepted

18 Years-70 Years

40 Estimated Participants

No Expanded Access

Interventional Study

Does not accept healthy volunteers

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Experience with substituting carboplatin for cisplatin is limited in advanced and recurrent cervix cancer and there has been no counterpart to GOG 158, which documented therapeutic equivalency of cisplatin/paclitaxel and carboplatin/paclitaxel for treatment of ovarian cancer, performed in a cervix cancer population.

This trial will be a prospective, randomized phase II pilot study. Consecutive patients of metastatic, recurrent or refractory carcinoma cervix enrolled in gynecology clinic at IRCH, AIIMS will be taken into study after taking informed consent. Patients will be randomized into two arms. Each arm shall contain 20 patients. The patients shall receive paclitaxel and carboplatin q3wk in first arm and paclitaxel and carboplatin q1 wk in second arm.

Eligibility

Relevant conditions:

Metastatic Carcinoma to the Uterine Cervix

Recurrent Carcinoma Cervix

Cervix Carcinoma Recurrent

If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.

locations

Contact Information

Overall Contact

No valid contacts available

Data sourced from ClinicalTrials.gov